The following is an illustrative, composite scenario built from patterns we see repeatedly across early-stage med device commercialization — not a real client engagement.
The Situation
A Series B medical device manufacturer had just received clearance for a monitoring device aimed at reducing a specific category of inpatient adverse events. The clinical data was solid. The founding team had genuine credibility — a couple of former hospital-side clinicians, an engineer with a track record. Investors were happy. Then came the part nobody had really planned for in detail: actually selling the thing to hospitals.
Like most startups in this position, the company had a hypothesis about its buyer. They assumed it was the clinical champion — a nurse manager or physician who'd get excited about the outcomes data and pull the device through procurement. They built their entire early go-to-market motion around that assumption: conference presence, clinical webinars, a sales rep who could speak fluently about sensitivity and specificity. Reasonable, on paper.
What Didn't Work
The first six months produced a lot of interested conversations and almost no signed deals. A few patterns showed up that are, frankly, almost universal in this stage of company:
They sold to people who don't buy. Clinical champions are real and they matter, but they are rarely the economic buyer, and they're almost never the person who can move a purchase through a health system's value analysis committee. The sales team kept closing enthusiasm, not contracts. Every "the nurses love this" conversation stalled the moment it hit supply chain or a VAC review, because nobody on the vendor side had built a relationship with the people actually sitting in that room — materials management, biomed, infection control, sometimes risk management depending on the device category.
They treated the health system as one account. The company's CRM had a single record for each hospital. In reality, they were selling into an IDN with a centralized value analysis process, semi-autonomous facility-level budgets, and a procurement team that operated on a cycle nobody had mapped. Outreach went to a generic "hospital administration" contact that either didn't exist as a functional role or belonged to someone with zero purchasing authority. The team didn't understand — because they hadn't done the org-mapping work — that the actual decision unit spanned three or four departments across two campuses, each with different priorities and different budget cycles.
They underestimated the sales cycle and overbuilt the pipeline math around it. Leadership had modeled a 4-6 month sales cycle based on comparable devices they'd researched. The real cycle, once VAC review, GPO contract checks, IT/security review (the device had connectivity), and capital budget timing were factored in, ran closer to 12-18 months for the accounts that eventually converted. The board was asking about pipeline velocity using assumptions that didn't match how hospitals actually buy capital equipment.
They confused interest for qualification. Marketing generated a decent volume of inbound interest from conference booths and clinical content, but almost none of it was scored or routed based on whether the person had any actual influence on purchasing. Reps spent months nurturing relationships with people who were clinically enthusiastic but organizationally irrelevant to the buying decision, while the real influencers — the value analysis coordinator, the biomed director who'd have to sign off on integration — were never identified, let alone contacted.
What Changed
The turning point wasn't a new sales hire or a slicker pitch deck. It was a shift in how the company thought about the account itself.
They stopped treating "the hospital" as a single lead and started mapping it as a buying committee with named roles: clinical champion, economic buyer, value analysis gatekeeper, technical/IT reviewer, and — critically — the person who controlled capital budget timing for that fiscal year. For each target account, they built out who actually sat in each seat, which meant investing time in understanding organizational structure at the health system level, not just facility level. This is where accurate, current org and contact data — the kind that reflects actual reporting lines and functional titles rather than a scraped directory listing — stops being a nice-to-have and starts being the thing that determines whether your rep is even talking to the right five people. NPLUS Global's healthcare data was one input the team used here, mainly to validate org structure and title accuracy before reps burned cycles on outdated contacts.
They also rebuilt the pipeline model around realistic cycle length, segmenting accounts by where they sat in fiscal year budget planning rather than by size or clinical fit alone. An account with perfect clinical alignment but a capital budget that had already closed for the year got deprioritized in favor of one with a live budget window, even if the clinical fit was less obvious. That reordering alone changed which accounts got attention in months 6 through 12.
Marketing shifted from broad clinical content toward materials aimed specifically at value analysis and procurement audiences — total cost of ownership framing, integration and workflow disruption specifics, comparative data against whatever the incumbent standard of care was. The clinical champion still mattered as an internal advocate, but the content built for the VAC reviewer was different in tone, length, and evidence type than what worked for the clinical audience, and the team stopped assuming one asset could do both jobs.
The Outcome
None of this compressed the sales cycle dramatically — hospital capital purchasing doesn't move fast no matter how good the targeting is. What it did was reduce wasted motion. Reps stopped spending months on accounts that had no realistic path to a signature within the fiscal year. The pipeline got smaller in raw count but more honest, and forecast accuracy improved enough that leadership could actually plan hiring and inventory around it instead of guessing.
By the end of year two, the company had a repeatable playbook for identifying the real buying committee in a given health system before the first sales call happened, rather than discovering it six months into a stalled deal. That's a modest-sounding outcome, but for a startup burning runway on a sales motion that wasn't converting, it was the difference between a commercialization strategy that worked and one that looked good in a board deck.
The underlying lesson wasn't really about sales technique. It was that most first-year med device go-to-market failures aren't caused by bad products or bad reps — they're caused by an inaccurate mental model of who's actually in the room when the purchase decision gets made.
Ready to see what we can build for your ICP?
Send us your ICP — sample in 2–3 hours, full delivery in 48–72 hours.
Request a free sample →